A Case Control Study on Psychopharmacotherapy before Suicide Committed by 61 Psychiatric Inpatients

Objective and Method: The pharmacotherapy of 61 suicide victims (0.24 % of 27,078 admissions from January 1, 1980 to December 31, 1999) was compared to that of a control group matched for age, gender and diagnosis at the time of discharge. Results: Both groups were also comparable regarding stay in hospital, history of psychiatric disease, and frequency of hospitalisations during the year preceding the index evaluation. Multiple but not single suicide attempts were significantly more frequent in patients who were later to complete the suicide than in controls. Schizophrenia (ICD-9, ICD-10) was the most frequent diagnosis among suicide victims (44.3 %). Affective psychosis (ICD-9, ICD-10) bore the highest relative risk (0.8 %). 50 % of the schizophrenic patients in the suicide group had been continuously treated with full-dose tricyclic antidepressants. The CPZ-equivalents in the patients treated with antipsychotics were not of discriminating value. Four of 27 schizophrenic patients in the suicide group had been off neuroleptics for ten days or more; this was never observed among the controls. Lorazepam applied in 40% of the schizophrenic and in 25 % of the affective psychosis suicide victims had more often been withdrawn or reduced during the ten days preceding suicide than among controls. No schizophrenic suicide victims but five controls had been on mood stabilisers. The use of antipsychotics (classical and atypical) and a recent change in tricyclic drug or drug dose were more frequent in suicide victims with affective psychosis. Lithium had been given to one patient, but it had also been administered to six controls; this difference is significant. Conclusion: Mood stabilisers, especially lithium, should be considered more often in patients with previous suicide attempt(s). When changing antidepressants in affective psychosis, benzodiazepines might be given more deliberate consideration. Patients in all diagnostic categories should be closely guided by means of intensified psychotherapeutic interventions while undergoing a benzodiazepine reduction. The treatment of patients suffering from schizophrenia with full-dose tricyclic regimens should be considered as possibly enhancing the acute suicide risk in some individuals.

References

• 1 Armbruster B. Suizide während der stationären psychiatrischen Behandlung.  Nervenarzt. 1886;  57 511-516
• 2 Cheng K K, Leung C M, Lo W H, Lam T H. Risk factors of suicide among schizophrenics.  Acta Psychiatr Scand. 1990;  81 220-224
• 3 Clark D C, Goebel-Fabbri A E. Lifetime risk of suicide in major affective disorders. In Jacobs DG, ed. Harvard Medical School Guide to Assessment and intervention in suicide. San Fransisco, Calif: Jossey-Bass 1999: 270-286
• 4 Coppen A. Lithium in unipolar depression and the prevention of suicide.  J Clin Psychiatry. 2000;  61 52-56
• 5 Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Silcocks P, Hermon C. Does lithium reduce the mortality of recurrent mood disorders?.  J Affect Disord. 1991;  23 1-7
• 6 Efinger T S. Soziodemographische Daten im Gruppenvergleich bei Patienten mit Suiziden und Suizidversuchen in der Psychiatrischen Klinik. Med Dissertation Tübingen 1998
• 7 Ernst K, Moser U, Ernst C. Zunehmende Suizide psychiatrischer Klinikpatienten: Realität oder Artefakt?.  Arch Psychiatr Nervenkr. 1980;  228 351-363
• 8 Finzen A. Der Patientensuizid: Untersuchungen, Analysen, Berichte zur Selbsttötung psychisch Kranker während der Behandlung. Psychiatrieverlag Bonn 1988
• 9 Foerster K, Gill A. Suicide während der stationären psychiatrischen Behandlung - zur Frage der Häufigkeit und der Vorhersehbarkeit.  Nervenarzt. 1987;  58 505-508
• 10 Harris C H, Barraclough B. Suicide as outcome for mental disorders.  Brit J Psychiatry. 1997;  170 205-228
• 11 Heilä H, Isometsä E T, Henriksson M M, Hewikkinen M E, Marttunen M J, Lönnqvist J K. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication.  J Clin Psychiatry. 1999;  60 200-208
• 12 Hogan T P, Awad A G. Pharmacotherapy and suicide risk in schizophrenia.  Can J Psychiatry. 1983;  28 277-281
• 13 International Classification of Diseases / 9^th Revision / 10^th Reversion, Chapter V (F): Mental and Behavioural Disorders (including disorders of psychological development).  Clinical Descriptions and Diagnostic Guidelines. World Health Organisation 1991
• 14 Krupinski M, Fischer A, Grohmann R, Engel R, Hollweg M, Möller H J. Risk factors for suicides of inpatients with depressive psychoses.  Eur Arch Psy Clin Neurosci. 1998;  248 141-147
• 15 Krupinski M, Fischer A, Grohmann R, Engel R, Hollweg M, Möller H J. Schizophrenic psychoses and inpatient suicide: risk factors and psychopharmacological treatment.  Nervenarzt. 2000;  71 906-911
• 16 Modestin J, Zarro I, Waldvogel D A. Study of suicide in schizophrenic in-patients.  Br J Psychiat. 1992;  160 398-401
• 17 Meltzer H Y. Suicide in Schizophrenia: risk factors and clozapine treatment.  J Clin Psychiat. 1998;  59 (3) 15-20
• 18 Meltzer H Y. Suicide and schizophrenia: Clozapine and the InterSePT Study.  J Clin Psychiat. 1999;  60 47-50
• 19 Meltzer H Y, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-assessment.  Am J Psychiat. 1995;  152 183-190
• 20 Müller-Oerlinghausen B, Ahrens B, Grof E, Grof P, Schou M, Simhandl C, Thau K, Volk J, Wolf R, Wolf T. The effect of long-term lithium treatment on the mortality of patients with manic-depressive and schizo-affective illness.  Acta psychiatr scand. 1992;  86 218-222
• 21 Müller-Oerlinghausen B, Wolf T, Ahrens B, Schou M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Wolf R. Mortallity during initial and during later lithium treatment. A collaborative study by the international Group for the study of lithium-treated patients.  Acta psychiatr scand. 1994;  90 295-297
• 22 Nilsson A. Lithium therapy and suicide risk.  J Clin Psychiat. 1999;  60 85-88
• 23 Rey M J, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics.  Int Clin Psychopharmacol. 1989;  4 95-104
• 24 Rossau C D, Mortensen P B. Risk factors for suicide in patients with schizophrenia: nested case-control study.  Brit J Psychiat. 1997;  171 335-339
• 25 Sharma V, Persad E, Kueneman K. A closer look at inpatient suicide.  J Affect Disorders. 1998;  47 23-129
• 26 Taiminen T J. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients.  Acta Psychiatr Scand. 1993;  87 45-47
• 27 Tondo L, Baldessarini R J. Reduced suicide risk during lithium maintenance treatment.  J Clin Psychiat. 2000;  61 97-104
• 28 Wolfersdorf M, Vogel R, Keller F, Hole G. The increase of suicides in psychiatric hospitals in southwestern Germany according to diagnostic subgroups.  Crisis. 1991;  12 34-47